MANATT, PHELPS, AND PHILLIPS

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · $70,000.00 income · posted Jan 13, 2026

Lobbying activity 1

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.